about
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.Nicotinamide metabolism regulates glioblastoma stem cell maintenance.Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma.Epigenomic alterations define lethal CIMP-positive ependymomas of infancyCancer stem cells in glioblastomaCDC20 maintains tumor initiating cells.Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.Preferential Iron Trafficking Characterizes Glioblastoma Stem-like CellsIdentification of alsterpaullone as a novel small molecule inhibitor to target group 3 medulloblastoma.Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age GroupsA Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo.RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation.Divergent clonal selection dominates medulloblastoma at recurrenceTherapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort AnalysisTERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma.Hypermutation of the inactive X chromosome is a frequent event in cancer.The genetic and epigenetic basis of ependymoma.The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants.Cytogenetic prognostication within medulloblastoma subgroups.Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome.The epigenetics of brain tumors.Emerging insights into the ependymoma epigenome.Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma.Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream.H3 K27M mutations are extremely rare in posterior fossa group A ependymoma.An epigenetic gateway to brain tumor cell identity.Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma."miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"PCDH10 is a candidate tumour suppressor gene in medulloblastoma.MLL5 Orchestrates a Cancer Self-Renewal State by Repressing the Histone Variant H3.3 and Globally Reorganizing Chromatin.Spatial heterogeneity in medulloblastoma."PEAR-ing" Genomic and Epigenomic Analyses for Cancer Gene Discovery.Evasion of p53 and G2/M checkpoints are characteristic of Hh-driven basal cell carcinoma.Nestin expression identifies ependymoma patients with poor outcome.MYC-Regulated Mevalonate Metabolism Maintains Brain Tumor-Initiating Cells.Purine synthesis promotes maintenance of brain tumor initiating cells in glioma.Targeting glioma stem cells through combined BMI1 and EZH2 inhibition.Impact of radiation therapy and extent of resection for ependymoma in young children: A population-based study.
P50
Q30613404-D5972B77-B1B9-4FD5-BBC0-F26DA6350389Q33703205-0F425380-CBD6-4FDF-94AB-918966057F9FQ34132926-F3191365-4AC1-448C-A16F-A64F832C854AQ34240198-BD2F1960-5F29-4ED6-A6D6-A1F71D1DFE45Q35829972-681B7D00-630D-4A66-9818-F989D06E3415Q35955263-7D87C32A-CDFE-4C00-A58D-DE6AFE30D765Q35958168-82412347-62A8-46E4-A107-027E22473F7AQ36282985-4E48D80A-9BA2-4B74-AD29-CC4C16AF502BQ36356443-C5F22494-1C81-45BC-AC9A-26E3B9562BE3Q36461766-EB945D0E-BAC8-4028-97ED-19BA28B5E060Q36917813-2B9F6AAF-E1EF-4393-B2AA-B357AB2B9C9DQ37042217-FC130200-0686-4920-97DD-449A37257429Q37073617-2F1ECC89-57A2-4AC2-B025-8373703095ABQ37130238-46FAB23E-CBF5-4E2B-B860-2C3F21889CADQ37316068-AD5BF16F-9BCE-4A30-B6E6-D632970525DFQ37503144-85FA0715-3CFF-4A12-AB94-EBDAA028FB92Q37523394-6F5B3D3B-7922-42E2-A482-902271CDA017Q37553466-17E88C56-5837-4293-B7E9-BCDB353BDAC9Q37627692-4C12C244-9CFF-42D4-A798-F405C319298FQ37642474-0A7C8396-8226-4F79-A34C-3F12239A8344Q37987505-0EBA96A1-B37B-4D96-8E19-F54236FDD187Q38083798-989D8A45-4FA1-4913-8EE2-DFE2D45074FFQ38120467-1FDA6AB3-DA4B-47A6-BC27-C389003B72A8Q38667981-A6EAFD1B-C041-49FA-BA76-1511F3BF05C8Q38670000-486BA7A3-06FB-4E5A-8226-9F17FCBB2632Q38682159-FEDCD20A-22B8-472E-9FC1-55FEC6689822Q38727361-5F87F9E2-5A24-47CB-AB55-02E8D880B508Q38940977-C766D733-CFB0-4915-92AD-1CE738CFFD77Q38954182-502FA7FD-7C8F-4B7A-B093-A0BF0F09CE1EQ39346476-56A9C64A-A1F3-46B1-BFBA-C03C47C790E0Q39539408-70370A68-DD1E-45E9-B8DC-2A3EA1F4C8C3Q41082397-A988F99D-4777-4B6E-AEF8-FDA38C2D7BB9Q41969132-9105B08D-2BC1-4FD6-B617-DAF7B9472B82Q42018327-3373D3E7-254F-467B-9AFE-D432B859C468Q42439705-42D79612-56F7-426B-A57E-A178B1B001FAQ43662312-21FF118C-56AB-4E92-80C8-943DCC7471B4Q45943224-D8E8D931-B819-473A-94E1-1308C7AA78BFQ47566392-9771C6CB-CB96-46D4-B6B3-CC22F519C1D7Q47648829-3FD8E06D-D369-4F97-AF94-37CF228331ABQ47852181-305519EC-4BAA-45D9-AB08-544C56E2BDA3
P50
description
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Stephen C Mack
@en
Stephen C Mack
@es
Stephen C Mack
@nl
Stephen C Mack
@sl
Stephen C. Mack
@de
type
label
Stephen C Mack
@en
Stephen C Mack
@es
Stephen C Mack
@nl
Stephen C Mack
@sl
Stephen C. Mack
@de
altLabel
Stephen C. Mack
@en
prefLabel
Stephen C Mack
@en
Stephen C Mack
@es
Stephen C Mack
@nl
Stephen C Mack
@sl
Stephen C. Mack
@de
P227
P101
P106
P21
P214
8821151595793105470005
P227
1150183934
P2798
P31
P496
0000-0001-9620-4742
P734
P735
P7859
viaf-8821151595793105470005